US EditionPublished • loading... • Updated
Tens of thousands of cancer patients to benefit from one-minute NHS jab
The new jab could cut treatment time by up to 90% and free NHS staff for more appointments, officials said.
- The NHS has begun rolling out a one-minute injectable immunotherapy for more than a dozen cancers, with early patients including 89-year-old Shirley Xerxes receiving treatment at Mount Vernon Cancer Centre in Hertfordshire.
- Previously, immunotherapy treatment required IV drips lasting up to 45 minutes using about 100mls of fluid; the new formulation slashes administration time by up to 90% and cuts staff preparation time by 44%.
- Around 14,000 patients start Pembrolizumab therapy annually in England, with most expected to switch to injections given every three or six weeks depending on cancer type.
- Professor Peter Johnson, NHS national clinical director for cancer, called the immunotherapy a "lifeline for thousands of patients," while Health and Social Care Secretary Wes Streeting said it offers "quicker, more convenient care."
- Reducing treatment time frees up vital appointments for NHS teams, enabling them to treat more patients and continue bringing down waiting times across oncology services.
Insights by Ground AI
15 Articles
15 Articles
NHS jab targeting dozens of cancers could slash treatment time by 90%
Tens of thousands of patients could benefit from a one-minute jab being rolled out on the NHS for more than a dozen cancers.The immunotherapy injection works by telling the body’s immune system to recognise and kill cancer cells and is powerful against several types of the disease, including lung, breast, head and neck, and cervical cancer.Until now, patients have had to spend long periods on a drip to get the drug pembrolizumab (Keytruda) into …
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources15
Leaning Left4Leaning Right1Center6Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 36%
C 55%
Factuality
To view factuality data please Upgrade to Premium
